Articles tagged "Immunosuppression"

2021 American Transplant Congress
Leflunomide Therapy for Treatment of Bk Viremia in Pediatric Kidney Transplant Recipients
A. Aldieri¹, M. Chandran², D. Matossian³, B. Magella⁴, D. Lazear⁴, M. Bock², E. Blanchette²
¹Children's Hospital Colorado, Denver, CO, ²Children's Hospital Colorado, Aurora, CO, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: BK viremia (BKV) after kidney transplantation (KT) poses significant risk for BK virus-associated nephropathy (BKVN) and impacts graft survival. Conventional treatment involves reduction of…
2021 American Transplant Congress
The Role of Notch2 in Antibody-mediated Alloimmune Response
R. Benedetti Gassen¹, N. Murakami², T. J Borges¹, A. Al Jurdi¹, A. Alessandrini¹, L. V Riella¹
¹Center of Transplantation Science, Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
*Purpose: Antibody mediated rejection is the leading cause of chronic allograft rejection. Developing a novel therapeutic target to inhibit chronic rejection is an urgent need…
2021 American Transplant Congress
Double Negative T Cells Mediate Cd39-Dependent Protection in Hepatic Ischemia and Reperfusion Injury
H. Jin, M. Li, C. Zhang, G. Sun, D. Zhang
Beijing Key Laboratory of Tolerance Induction and Organ Protection in Transplantation, Beijing Friendship Hospital, Capital Medical University, Beijing, China
*Purpose: Hepatic ischemia and reperfusion injury (HIRI) is a significant cause of morbidity and mortality following liver transplantation and major hepatic resections. Double negative T…
2021 American Transplant Congress
Influence of Immunosuppressive Drug Trough Levels on Nk Cells in Liver Transplantation
R. Qin¹, J. Qin², C. Sun³, B. Nashan¹
¹Clinic for Organ Transplantation, The First Affiliated Hospital of the University of Science and Technology of China, Hefei, China, ²Clinic for Organ Transplantation, The First Affiliated Hospital of the University of Science and Technology of China., Hefei, China, ³Division of Life and Medicine, University of Science and Technology of China, Hefei, China
*Purpose: Natural killer (NK) cells are enriched in lymphocytes within the liver and are considered to be main regulators of liver transplantation (LT) rejection and…
2021 American Transplant Congress
Infection Rates in Heart Transplant Recipients With Combined Tacrolimus and Sirolimus at High versus Low Concentrations
S. Goyal, J. Lyons, J. Negrelli, M. Liebo, A. Heroux
Loyola University Medical Center, Maywood, IL
*Purpose: Assess the impact of tacrolimus-sirolimus (TAC/SRL) concentration on infection rate in heart transplant recipients (HTR).*Methods: A retrospective review of HTR on TAC/SRL for ≥…
2021 American Transplant Congress
Belatacept Conversion in Elderly Renal Transplant Recipients
M. Durst¹, D. Felix¹, M. Jorgenson¹, J. Descourouez¹, B. C. Astor², D. Mandelbrot²
¹UW Health, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
*Purpose: Describe the impact of conversion from a calcineurin inhibitor (CNI) based immunosuppressive regimen to belatacept in elderly renal transplant recipients.*Methods: Adult renal transplant patients…
2021 American Transplant Congress
Post Pediatric Liver Transplant Immunosuppression: What’s the Caregivers’ Perspective?
I. D. Batsis¹, J. C. Bucuvalas¹, E. Eisenberg², J. Lau², S. Feng³, E. Perito⁴
¹Pediatric Hepatology, Mount Sinai Hospital, NY, New York, NY, ²Patient and Family Engaged Partners, SPLIT, New York, NY, ³Pediatric Transplant Surgery, UCSF, San Francisco, CA, ⁴Pediatric Hepatology, UCSF, San Francisco, CA
*Purpose: For children with liver transplants (LT), achieving an “ideal outcome” is a balancing act: too little immunosuppression (IS) begets graft injury; too much IS…
2021 American Transplant Congress
Role of Baseline PD-1 Checkpoint Inhibitor Pathway Expression in Bridge to Liver Transplant Hepatocellular Carcinoma
K. Nunez, T. Sandow, M. Hibino, A. Cohen, P. Thevenot
Ochsner Health, New Orleans, LA
*Purpose: Response to first line liver-directed therapy (LDT) in hepatocellular carcinoma (HCC) has important implications in both bridge to transplant (BTT) success as well as…
2021 American Transplant Congress
Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
M. McGowan¹, A. Bickenbach¹, B. Miyagawa², A. Christianson¹, T. Mizuno², P. West-Thielke³, J. Leone⁴, E. Woodle¹, D. Kaufman⁵, A. Wiseman⁶, A. Matas⁷, A. Vinks², R. Alloway¹
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Children's Med Center, Cincinnati, OH, ³U Illinois, Chicago, IL, ⁴Tampa Gen, Tampa, FL, ⁵U Wisconsin, Madison, OH, ⁶Centura Transplant, Denver, CO, ⁷U Minnesota, Minneapolis, MN
*Purpose: Phase 1 and 2 belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies. PK data from these studies revealed higher BELA troughs on Day…
2021 American Transplant Congress
Nanoparticle Mediated Drug Delivery for Lung Transplantation
P. M. Patel¹, S. Jung², C. L. Miller¹, J. M. O¹, T. Costa¹, A. Dehnadi¹, I. Hanekamp¹, X. F. Li², L. Jiang², H. Ichimura², A. Azimzadeh¹, J. C. Madsen³, R. Abdi²
¹Surgery, Center for Transplantation Sciences, Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²Medicine, Transplant Research Center, Brigham and Women's Hospital, Boston, MA, ³Surgery, Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, MA
*Purpose: Severe primary graft dysfunction (PGD) affects 30% of lung transplant patients. Pulmonary alveolar macrophages play a significant role in lung PGD, but systemic immunotherapy…